Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2025;31(3):1105-1106. Published online July 1, 2025
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2024;30(3):487-499. Published online May 7, 2024
Background/Aims To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort.
Methods Information on study participants was derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. The association of evolutionary changes in MASLD status, as assessed by the fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using multivariable-adjusted Cox proportional hazards regression.
Results Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), incident (aHR, 1.85; 95% CI, 1.63–2.10; P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, 1.18–1.50; P<0.001) had an increased risk of HCC compared to persistent non-MASLD.
Conclusions The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.
Citations
Citations to this article as recorded by
Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction–associated steatotic liver disease in a longitudinal study Xuangao Wu, Ting Zhang, Sunmin Park Nutrition.2025; 130: 112604. CrossRef
A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(1): 126. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef
Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Hai Xu, Yong Zhou, Huikun Wu Clinical and Molecular Hepatology.2025; 31(2): e125. CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef
Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song Clinical and Molecular Hepatology.2025; 31(2): e128. CrossRef
Significant hepatic fat loss after metabolic dysfunction-associated steatotic liver disease: Beware of misclassification as absence of disease Seogsong Jeong Journal of Hepatology.2025; 83(3): e156. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah Metabolites.2025; 15(5): 299. CrossRef
Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang Phytomedicine.2025; 143: 156889. CrossRef
Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases Jialong Wu, Gonghua Wu, Jiawei Li, Bo Yi, Qingyi Jia, Ke Ju, Qingyang Shi, Zixuan Wang, Xiong Xiao, Bing Guo, Huan Xu, Xing Zhao European Journal of Endocrinology.2025; 192(5): 691. CrossRef
Association between green space and hepatocellular carcinoma risk: a retrospective cohort study of seven South Korean metropolitan areas Dong Hyun Kim, Seulggie Choi, Seogsong Jeong, Jooyoung Chang, Sung Min Kim, Sun Jae Park, Jun Hwan Kim, Joung Sik Son, Gyeongsil Lee, Soo Jung Choi, Yun Hwan Oh, Kyae Hyung Kim, Sang Min Park International Journal of Environmental Health Research.2025; 35(12): 4026. CrossRef
Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755. CrossRef
Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi PLOS One.2025; 20(6): e0323880. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-analysis Ryan Yanzhe Lim, Faith Xin Ning Tan, Glenn Jun Kit Ho, Ethan Kai Jun Tham, Alfred Kow, Guoyue Lv, Zhong-Qi Fan, Nicholas Syn, Masahito Nakano, Wenhao Li, Karn Wijarnpreecha, Jörn M. Schattenberg, Vincent Chen, Ming-Hua Zheng, Pojsakorn Danpanichkul, Hirok Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma Dingwu Li, Xiang Zhang Hepatology Communications.2025;[Epub] CrossRef
A Mediterranean-style diet protects against cognitive and behavioral deficits, adiposity, and Alzheimer's disease-related markers, compared to a macronutrient-matched typical American diet in C57BL/6J mice Paige N Braden-Kuhle, Vivienne A Lacy, Kelly N Brice, Morgan E Bertrand, Hatice Buse Uras, Catherine Shoffner, Bridgette E Fischer, Ashish Rana, Jada L Willis, Gary W Boehm, Michael J Chumley Journal of Alzheimer’s Disease.2025; 104(3): 678. CrossRef
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park
Clin Mol Hepatol 2022;28(3):510-521. Published online March 17, 2022
Background/Aims Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was conducted to determine the association between NAFLD and incident dementia.
Methods The study population included 608,994 adults aged ≥60 years who underwent health examinations between 2009 and 2010. Data were collected from the Korean National Health Insurance Service database. NAFLD was assessed using the fatty liver index (FLI). A Cox proportional hazards regression model was used to determine the association between NAFLD and dementia.
Results During the 6,495,352 person-years of follow-up, 48,538 participants (8.0%) developed incident dementia. The participants were classified into low (FLI <30), intermediate (FLI ≥30 and <60), and high (FLI ≥60) groups. In the overall study population, the FLI groups were associated with a risk of dementia (P for trend <0.001). After propensity score matching, a low FLI was associated with a reduced risk of dementia (adjusted hazard ration [aHR], 0.96; 95% confidence interval [CI], 0.93–0.98; P=0.002), whereas a high FLI (NAFLD) was associated with an increased risk of dementia (aHR, 1.05; 95% CI, 1.02–1.08; P=0.001). A higher risk of dementia in the high FLI group than in the intermediate FLI group was attributed to Alzheimer’s disease (aHR, 1.04; 95% CI, 1.01–1.07; P=0.004) rather than vascular dementia (aHR, 0.94; 95% CI, 0.75–1.18; P=0.602).
Conclusions NAFLD was associated with an increased risk of dementia, which was attributed to an increased risk of Alzheimer’s disease.
Citations
Citations to this article as recorded by
Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration Evridiki Asimakidou, Eka Norfaishanty Saipuljumri, Chih Hung Lo, Jialiu Zeng Neural Regeneration Research.2025; 20(4): 1069. CrossRef
Associations of metabolic dysfunction-related fatty liver disease and dementia risk: A prospective study based on the UK biobank Chaofan Geng, Peiyang Gao, Yi Tang Archives of Gerontology and Geriatrics.2025; 135: 105845. CrossRef
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease Is Associated With Accelerated Brain Ageing: A Population‐Based Study Jiao Wang, Rongrong Yang, Yuyang Miao, Xinjie Zhang, Stéphanie Paillard‐Borg, Zhongze Fang, Weili Xu Liver International.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho BMC Gastroenterology.2025;[Epub] CrossRef
A cross sectional study of the diabetes mediated GGT to HDL ratio and cognitive function in older adults Ye Wang, Yanping Mao, Tianmei Xu, Lujie Han, Wenxuan Zhang, Wangdi Sun, Jiaxi Xu, Enyan Yu Scientific Reports.2025;[Epub] CrossRef
Exploring LRP-1 in the liver-brain axis: implications for Alzheimer’s disease Vivek Kumar Sharma Molecular Biology Reports.2025;[Epub] CrossRef
Association between fatty liver index and low back pain: A cross-sectional study from NHANES 1999–2004 Jiangtao Liao, Zhenyu Song, Hao Xu, Yi Li, Dongdong Xu, Hongtao Tian, Zhipeng Dai, Wei Tong Journal of Back and Musculoskeletal Rehabilitation.2025;[Epub] CrossRef
MASLD in the oldest-old: lack of association with cognition or functional autonomy and poor predictive utility of the hepatic steatosis index Maximilian Joseph Brol, Martin Groth, Frank Erhard Uschner, Juliana Stadtmann, Tina Schomacher, Jonel Trebicka, Michael Praktiknjo, Elena Vorona GeroScience.2025;[Epub] CrossRef
Liver integrity and the risk of Alzheimer's disease and related dementias Yifei Lu, James Russell Pike, Ron C. Hoogeveen, Keenan A. Walker, Laura M. Raffield, Elizabeth Selvin, Christy L. Avery, Stephanie M. Engel, Michelle M. Mielke, Tanya Garcia, Priya Palta Alzheimer's & Dementia.2024; 20(3): 1913. CrossRef
Disentangling the contributions of alcohol use disorder and alcohol‐related liver disease towards dementia: A population‐based cohort study Sixian Zhao, Linnea Widman, Hannes Hagström, Ying Shang Addiction.2024; 119(4): 706. CrossRef
The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review Mauro Giuffrè, Nicola Merli, Maura Pugliatti, Rita Moretti International Journal of Molecular Sciences.2024; 25(6): 3337. CrossRef
Factor modification in the association between high-density lipoprotein cholesterol and liver cancer risk in a nationwide cohort Su Youn Nam, Junwoo Jo, Won Kee Lee, Chang Min Cho International Journal of Epidemiology.2024;[Epub] CrossRef
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease Andrey Tsoy, Bauyrzhan Umbayev, Aliya Kassenova, Bibifatima Kaupbayeva, Sholpan Askarova International Journal of Molecular Sciences.2024; 25(20): 10964. CrossRef
Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen Fibrosis.2024; 2(4): 10006. CrossRef
Association between composite dietary antioxidant index and fatty liver index among US adults Meng Zheng, Chaochen Li, Jia Fu, Long Bai, Jinghui Dong Frontiers in Nutrition.2024;[Epub] CrossRef
Association between dementia, Alzheimer's disease, and liver cancer: A Mendelian randomization analysis Tianze Li, Jianwei Yi, Xuliang Hu, Huajun Wu, Kai Wang, Binghai Zhou Journal of Alzheimer's Disease Reports.2024; 8(1): 1587. CrossRef
Association of Balance Impairment with Risk of Incident Dementia among Older Adults H.J. Kim, S. Jeong, Yun Hwan Oh, Michelle J. Suh, Jee Young Suh The Journal of Prevention of Alzheimer's Disease.2024; 11(1): 130. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration Taylor J. Kelty, Ryan J. Dashek, W. David Arnold, R. Scott Rector Seminars in Liver Disease.2023; 43(01): 077. CrossRef
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh Frontiers in Endocrinology.2023;[Epub] CrossRef
NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis Hangkai Huang, Zhening Liu, Jiarong Xie, Chengfu Xu Journal of Psychiatric Research.2023; 161: 435. CrossRef
Effect of Comorbidities on Ten-Year Survival in Patients with Dementia Nida Buawangpong, Kanokporn Pinyopornpanish, Phichayut Phinyo, Wichuda Jiraporncharoen, Chaisiri Angkurawaranon, Atiwat Soontornpun Journal of Alzheimer’s Disease.2023; 94(1): 163. CrossRef
Regulation of mild cognitive impairment associated with liver disease by humoral factors derived from the gastrointestinal tract and MRI research progress: a literature review Tianning Sun, Maohui Feng, Anne Manyande, Hongbing Xiang, Jun Xiong, Zhigang He Frontiers in Neuroscience.2023;[Epub] CrossRef
Impact of ectopic fat on brain structure and cognitive function: A systematic review and meta-analysis from observational studies Zhi-Hui Song, Jing Liu, Xiao-Feng Wang, Rafael Simó, Chao Zhang, Jian-Bo Zhou Frontiers in Neuroendocrinology.2023; 70: 101082. CrossRef
Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(3): 817. CrossRef
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef
Association of Thyroid Hormone Medication Adherence With Risk of Dementia Saemi Han, Seogsong Jeong, Seulggie Choi, Sun Jae Park, Kyae Hyung Kim, Gyeongsil Lee, Yoosun Cho, Joung Sik Son, Sang Min Park The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e225. CrossRef
Sex-specific relationship between non-alcoholic fatty liver disease and amyloid-β in cognitively unimpaired individuals Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Mira Kang, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Yoosoo Chang, Sang Won Seo Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population Pei Zeng, Xiangsheng Cai, Xiaozhou Yu, Lu Huang, Xi Chen Journal of International Medical Research.2023;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim eClinicalMedicine.2023; 65: 102292. CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Non‐alcoholic fatty liver disease and the risk of dementia—Authors' reply Gi‐Ae Kim, Jae‐Jun Shim Liver International.2022; 42(8): 1914. CrossRef
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults Byoung Seok Ye Clinical and Molecular Hepatology.2022; 28(3): 481. CrossRef
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung Clinical and Molecular Hepatology.2022; 28(4): 931. CrossRef
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2022; 28(4): 933. CrossRef
Dementia and non-alcoholic fatty liver disease – An unprecedented relationship Fakhar Latif, Vania Saqib, Eisha Waqar Annals of Medicine and Surgery.2022; 81: 104359. CrossRef
Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis Luping Wang, Bowen Sang, Zuyan Zheng Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
First
Prev
